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Objectives: SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium
difficile infection (CDI). The objective was to determine the comparative susceptibility of 82 C. difficile clinical iso-
lates (which included ribotype 027 isolates and isolates with reducedmetronidazole susceptibility) to SMT19969,
fidaxomicin, vancomycin and metronidazole and to determine the killing kinetics and post-antibiotic effects of
SMT19969, fidaxomicin and vancomycin against C. difficile.
Methods: MICs were determined by agar incorporation. Killing kinetics and post-antibiotic effects were deter-
mined against C. difficile BI1, 630 and 5325 (ribotypes 027, 012 and 078, respectively).
Results: SMT19969 showed potent inhibition of C. difficile (MIC90¼0.125 mg/L) and was markedly more active
than eithermetronidazole (MIC90¼8 mg/L) or vancomycin (MIC90¼2 mg/L). Therewere no differences in suscep-
tibility to SMT19969 between different ribotypes. Fidaxomicin was typically one doubling dilution more active
than SMT19969 and both agents maintained activity against isolates with reduced susceptibility to metronida-
zole. In addition, SMT19969was bactericidal against the C. difficile strains tested, with reductions in viable counts
to below the limit of detection by 24 h post-inoculation. Vancomycin was bacteriostatic against all three
strains. Fidaxomicin was bactericidal although reduced killing was observed at concentrations,20×MIC against
C. difficile BI1 (ribotype 027) compared with other strains tested.
Conclusions: These data demonstrate that SMT19969 is associated with potent and bactericidal activity against
the strains tested and support further investigation of SMT19969 as potential therapy for CDI.
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Introduction
Clostridium difficile infection (CDI) is a significant cause of morbid-
ity and mortality in both the acute care setting and the wider
healthcare system.1,2 The global increase in the incidence of CDI
is driven, in part, by the emergence of fluoroquinolone-resistant
ribotype 027 C. difficile strains,3 which continue to account for
30% of CDI cases in North America.4 These strains are asso-
ciated with poor outcomes, including reduced cure rates and
increased rates of recurrent disease.5,6 Although the prevalence
of ribotype 027 was thought to have declined in Europe,7 the
recent EUCLID study demonstrates the dominance of ribotype
027 in Central and Eastern Europe.8 Also, new hyper-virulent
strains such as ribotype 244 continue to emerge.9
CDI pathogenesis is associated with antimicrobial use that
causes reduced diversity of the gut microbiota, thus reducing
the host’s ability to resist colonization by, and expansion of,
C. difficile. These conditions allow C. difficile spores to germinate,
with resultant toxin production leading to disease symptoms.
Vancomycin and metronidazole, the mainstay antibiotics used
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in CDI, have been shown to cause further collateral damage to the
gut microbiota,10 –12 and analysis of the gut microbiome of CDI
patients has shown that recurrent disease is associated with a
markedly decreased diversity in the bacterial populations of the
gut.13 As such, therapeutic approaches that minimize further
deleterious effects to the gut microbiota may reduce rates of
recurrent CDI.
SMT19969 is a novel antimicrobial under specific development
for CDI that shows potent inhibition of C. difficile, but is associated
with minimal growth inhibition of both Gram-positive and
Gram-negative components of the indigenous gutmicroflora;14,15
such focused activity may result in reduced rates of recurrent dis-
ease. The following studies further assessed and compared
growth inhibition by, and the in vitro pharmacodynamics of,
SMT19969, fidaxomicin, vancomycin and metronidazole against
C. difficile.
Materials and methods
Test agents
SMT19969 (supplied by Summit plc, Abingdon, UK), fidaxomicin [obtained
from Cubist Pharmaceuticals, Lexington, MA, USA (for MIC determination)
and from Santa Cruz Biotechnology, Santa Cruz, CA, USA (for kill curve and
post-antibiotic effect, PAE, assays)] andmetronidazole (supplied by Sigma)
were reconstituted in DMSO prior to further dilution. Vancomycin (supplied
by Sigma) stock solutions were prepared in water.
Bacterial strains
Susceptibility testing was carried out using C. difficile clinical isolates col-
lected in the UK from subjects with CDI. All isolates had been submitted to
the C. difficile ribotyping network. A total of 82 C. difficile isolates were
assessed across five panels comprising 30 distinct isolates of different
PCR ribotypes (referred to as the genotypically distinct group), 10 PCR ribo-
type 001 isolates, 11 PCR ribotype 027 isolates, 10 PCR ribotype 106 iso-
lates and 21 PCR ribotype 001 isolates showing reduced metronidazole
susceptibility (MIC 4–8 mg/L).16 Staphylococcus aureus ATCC 29213,
Bacteroides fragilis ATCC 25285 and C. difficile PCR ribotype 010 E4 were
used as control organisms. C. difficile E4 is a non-toxigenic PCR ribotype
010 internal control strain.17
Kill curve and PAE studies were performed using C. difficile 630 (ATCC
BAA 1382; ribotype 012), BI1 (NCTC 13366; ribotype 027) and 5325
(ATCC BAA-1875; ribotype 078).
MICs
Comparative susceptibility testing was carried out on Wilkins Chalgren
agar due to the superior growth compared with Brucella agar and also
the ability to detect reduced susceptibility to metronidazole.16 MICs
were determined byagar incorporation according to a previously validated
method.16 All isolates were tested in duplicate for susceptibility to
SMT19969, fidaxomicin, vancomycin and metronidazole.
For the kill curve and PAE studies, MIC values (Table 1) were established
for SMT19969, fidaxomicin and vancomycin by broth microdilution using
BHIS medium (brain heart infusion broth supplemented with 5 g/L yeast
extract and 0.025% L-cysteine); this medium was used in order to be con-
sistent with later experiments.
Killing kinetics
Cultures of C. difficilewere prepared by inoculating fresh, pre-reduced BHIS
medium with a single colony of the required strain. Following overnight
(18–20 h) incubation, cultures were back-diluted 1:100 into fresh BHIS
broth (106 cfu/mL) containing either DMSO (1% v/v; vehicle) or 1, 2, 5,
10 or 20×MIC of SMT19969, vancomycin or fidaxomicin. Viable counts
were determined at 0, 2, 4, 6, 8 and 24 h post-inoculation on BHIS agar.
Data presented are themeans of triplicate experiments. The limit of detec-
tion (LOD) for these assays was 500 cfu/mL. A≥3 log10 reduction in viabil-
ity relative to the starting inoculum was considered bactericidal.
PAE
Cultures of C. difficile were prepared in 15 mL polypropylene centrifuge
tubes in the presence of DMSO or antibiotic, as described above. Cultures
were incubated for 1 h before being collected by centrifugation (4696 g,
5 min, 258C), washed once with BHIS to remove test articles and finally
re-suspended in fresh BHIS. For assays involving exposure to fidaxomicin,
cultures were transferred to sterile glass bijou tubes following removal of
the test article in order to minimize drug carryover due to non-specific
binding as previously reported.18 Centrifugation was the only step per-
formed outside the anaerobic workstation. At this point, samples were
removed for determination of viable counts (0 h) and further samples
were removed for counting after 2, 4, 6, 8 and 24 h. The LOD for these
experiments was 50 cfu/mL. The PAE of each test article was defined as
PAE¼T2C, where T is the time required for determination of the viable
count to increase 10-fold over the post-washing viable count in the pres-
ence of antibiotic, and C is the time required for the viable count to
increase 10-fold over the post-washing viable count in the absence of anti-
biotic. The mean values obtained from three independent experiments
were used for T and C. PAE (in hours) was estimated to the nearest time-
point. Where the PAE endpoint was reached overnight, the endpoint was
defined as the limits of the PAE (i.e. 8–20 h). No interpolation between
timepoints was attempted.
Results
Susceptibility testing
The comparative susceptibilities of 82 C. difficile clinical isolates to
SMT19969, fidaxomicin, metronidazole and vancomycin are
shown in Table 2. Vancomycin generally maintained a consistent
level of activity against the majority of the panels assessed with
an MIC90 of 2 mg/L (typical range¼0.5–4 mg/L) for each panel
except for the metronidazole-susceptible ribotype 001 panel
where an MIC90¼4 mg/L was recorded. Although the vast major-
ity of the 82 isolates had vancomycin MIC values of 1 or 2 mg/L,
seven isolates (ribotypes 056, 001, 027 and 106) showed an ele-
vated MIC value of 4 mg/L. Susceptibility to metronidazole was
more varied across the panels. For ribotypes 027 and 106, MIC50
values were one dilution higher than for the metronidazole-
susceptible ribotype 001 panel, and two dilutions higher than
MIC50 values recorded for the genotypically distinct group.
Both fidaxomicin and SMT19969 showed potent activity
against the 82 isolates tested, with MIC90 values of 0.06 mg/L
(range¼0.008–0.125 mg/L) and 0.125 mg/L (range¼0.06–
Table 1. Reference MICs established by broth microdilution for killing
kinetics and PAE studies
C. difficile strain (ribotype)
MIC (mg/L)
SMT19969 vancomycin fidaxomicin
BI1 (027) 0.125 4 0.25
630 (012) 0.125 4 0.25
5325 (078) 0.125 1 0.25
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0.25 mg/L), respectively, which was typically 16–32-fold lower
than the MIC90 values recorded for either vancomycin against
the 82 isolates or metronidazole against the metronidazole-
susceptible isolates. Fidaxomicin showed increased potency com-
pared with SMT19969 with MIC90 values one dilution and MIC50
values two dilutions lower than those recorded for SMT19969.
SMT19969 activity was consistent across different ribotypes,
including ribotype 027 isolates; the MIC90 for each panel of clinical
isolates was 0.125 mg/L. Similarly, fidaxomicin showed highly
consistent activity against the strains tested, although it was
slightly less active against ribotype 106 compared with the other
isolates. For the PCR ribotype 001 isolates showing reduced suscep-
tibility to metronidazole, both vancomycin and SMT19969 main-
tained activity levels comparable to those observed against the
metronidazole-susceptible ribotype 001 strains, whilst fidaxomicin
MIC90 values were one dilution lower (0.03 versus 0.06 mg/L).
Overall SMT19969 showed potent growth inhibition of the 82
isolates tested, with an MIC90 of 0.125 mg/L, which was 16-fold
lower than the MIC90 values recorded for vancomycin against
the 82 isolates and the 61 metronidazole-susceptible isolates.
Killing kinetics
The comparative killing kinetics of SMT19969, vancomycin and
fidaxomicin were assessed against C. difficile strains BI1 (ribotype
027), 630 (ribotype 012) and 5325 (ribotype 078). Kill curves for
vancomycin, fidaxomicin and SMT19969 against C. difficile BI1
are shown in Figures 1–3, with reductions in cfu/mL for C. difficile
630 and 5325 following 24 h of exposure to antibiotic shown in
Table 3. It should be noted that the starting inoculum for
experiments with fidaxomicin and C. difficile 630 and 5325 was
somewhat lower (3.72×105 and 2.17×105 cfu/mL, respectively)
Table 2. MICs of SMT19969, fidaxomicin, metronidazole and vancomycin for 82 C. difficile clinical isolates
Panel (n) Agent MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L)
Genotypically distinct (30)a SMT19969 0.06–0.125 0.125 0.125
vancomycin 1–4 2 2
metronidazole 0.25–2 0.5 2
fidaxomicin 0.008–0.125 0.03 0.06
Ribotype 001 (10) SMT19969 0.06–0.125 0.125 0.125
vancomycin 0.5–4 1 4
metronidazole 0.125–1 1 1
fidaxomicin 0.008–0.06 0.03 0.06
Ribotype 027 (11) SMT19969 0.125–0.25 0.125 0.125
vancomycin 0.5–4 1 2
metronidazole 1–2 2 2
fidaxomicin 0.03–0.06 0.06 0.06
Ribotype 106 (10) SMT19969 0.125–0.25 0.125 0.125
vancomycin 0.5–4 1 2
metronidazole 1–2 2 2
fidaxomicin 0.03–0.125 0.06 0.125
Reduced metronidazole susceptibility (21)b SMT19969 0.06–0.125 0.125 0.125
vancomycin 0.5–4 1 2
metronidazole 4–8 4 8
fidaxomicin 0.015–0.03 0.03 0.03
Overall total (82) SMT19969 0.06–0.25 0.125 0.125
vancomycin 0.5–4 1 2
metronidazole 0.125–8 2 8
fidaxomicin 0.008–0.125 0.03 0.06
aThirty distinct isolates of different PCR ribotype.
bRibotype 001.
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Figure 1. Twenty-four hour time–kill curves for vancomycin against
C. difficile BI1. Data are the means (+SD) of triplicate experiments.
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than for vancomycin (1.94×106 and 9.00×105 cfu/mL) or
SMT19969 (3.28×106 and 1.42×106 cfu/mL). Starting inocula
for experiments with C. difficile BI1 for SMT19969, fidaxomicin and
vancomycin were 7.50×105, 1.30×106 and 3.17×106 cfu/mL,
respectively.
Vancomycin generally achieved a slow reduction in bacterial
counts of C. difficile BI1, resulting in a 1.5–2.5 log10 reduction in
viability after 24 h (Figure 1); a 3.1 log10 reduction in cfu/mL was
observed at 24 h at 2×MIC. Similarly, fidaxomicin at 1–10×MIC
was bacteriostatic against C. difficile BI1 with a 1.5–2.0 log10
reduction in viable counts. At 20×MIC, fidaxomicin was bacteri-
cidal, resulting in a 3.3 log10 reduction in viable counts after
24 h of exposure (Figure 2). All concentrations of SMT19969
resulted in a reduction in viable counts to below the LOD
(.3.2 log10 reduction in cfu/mL) at 24 h (Figure 3). Killing by
SMT19969 was independent of drug concentration.
The viability of C. difficile strain 630when exposed to vancomy-
cin and SMT19969 over 24 h was similar to that observed for
C. difficile BI1. Vancomycin gradually reduced the viability of
C. difficile 630 over time in a concentration-independent manner,
although a greater reduction in viable counts, compared with
C. difficile BI1, of 3.0–3.6 log10 was observed at 24 h (Table 3).
As observed with BI1, SMT19969 was bacteriostatic to 8 h with
reductions in viable counts to below the LOD (.3.8 log10) at con-
centrations ≥5×MIC. Fidaxomicin was more effective at killing
C. difficile 630 than C. difficile BI1, with counts reduced below
the LOD by 6 h (20×MIC) or 24 h (2–10×MIC).
Against C. difficile 5325, vancomycin was bacteriostatic at
all concentrations tested (Table 3). Consistent with observations
for strains 630 and BI1, all tested concentrations of SMT19969
were bacteriostatic for 8 h. Between 8 and 24 h, counts of
C. difficile 5325 fell by ≥3 log10 cfu/mL at concentrations
.5×MIC (Table 3). Fidaxomicin resulted in a marked decrease
in viable counts, with concentrations ≥5×MIC resulting in loss
of viability of C. difficile to below the LOD by 24 h (Table 3). At
20×MIC, fidaxomicin rapidly reduced cell viability to below the
LOD by 6 h.
PAE
The PAE of each antibiotic was established against C. difficile BI1,
630 and 5325 by monitoring the growth of each strain following
a 1 h exposure to 1, 2, 5, 10 or 20×MIC of the drug. Recovery of
C. difficile BI1 following pre-exposure to SMT19969 is shown in
Figure 4, with calculated PAEs for all drug–strain combinations
shown in Table 4.
SMT19969 had a PAE of 2 h for C. difficile BI1 at 5×MIC with
concentrations of 10 or 20×MIC suppressing growth for ≥8 h.
At 20×MIC, C. difficile BI1 did not recover with a 2 log10 reduction
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Figure 3. Twenty-four hour time–kill curves for SMT19969 against
C. difficile BI1. Data are the means (+SD) of triplicate experiments.
Table 3. Mean log10 cfu/mL reductions for C. difficile 630 and 5325
following 24 h of exposure to SMT19969, vancomycin or fidaxomicin
Strain Agent
Mean log10 reductions in cfu/mL
1×MIC 2×MIC 5×MIC 10×MIC 20×MIC
630 SMT19969 3.61 2.17 .3.82a .3.82a .3.82a
vancomycin 3.25 3.22 2.99 3.46 3.59
fidaxomicin 2.45 .2.87a .2.87a .2.87a .2.87a
5325 SMT19969 2.60 1.62 2.73 3.16 3.33
vancomycin 1.14 2.65 1.82 1.81 1.46
fidaxomicin 2.41 2.16 .2.64a .2.64a .2.64a
aReduced to below LOD.
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Figure 4. PAE of SMT19969 against C. difficile BI1. Data are the means
(+SD) of triplicate experiments. Drug removed at 0 h.
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Figure 2. Twenty-four hour time–kill curves for fidaxomicin against
C. difficile BI1. Data are the means (+SD) of triplicate experiments.
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in viable counts at 24 h post-removal of SMT19969 (Figure 4).
Fidaxomicin had a pronounced PAE (8–20 h) at concentrations
≥2×MIC. At 20×MIC of fidaxomicin, inconsistent recovery of bac-
teria was observed with a 1–2 log10 reduction in viability noted in
two out of three replicates (complete recovery was seen in the
third replicate; Table 4). Vancomycin showed no measurable PAE
against C. difficile BI1 (Table 4).
At all tested concentrations, a 1 h exposure to vancomycin
resulted in a PAE of 0–2 h for C. difficile 5325 (Table 4).
SMT19969 concentrations of 10×MIC were required to produce
a quantifiable PAE of 4 h. At 20×MIC of SMT19969, inconsistent
recovery of C. difficile 5325 was observed (viability in two out of
three replicates reduced below the LOD). Fidaxomicin concentra-
tions ≥MIC had a prolonged PAE of 8–20 h. At 20×MIC, the
growth of the culture remained suppressed at 24 h post-removal
of antibiotic, with a concomitant 2 log10 reduction in viable
counts.
For C. difficile 630, the PAE of vancomycin was,2 h for concen-
trations from 1 to 10×MIC, whilst at 20×MIC a PAE of 2 h was
observed. SMT19969 exhibited a PAE of 2–4 h up to 10×MIC
(Table 4). At 20×MIC of SMT19969, counts of C. difficile 630 fell
below the LOD by 24 h post-removal of SMT19969. Fidaxomicin
showed a prolonged (8–20 h) PAE against strain 630 at concen-
trations between 1 and 5×MIC whilst at higher concentrations
no growth was observed with the viability of the culture reduced
2.4 log10 in the 24 h following removal of antibiotic.
Discussion
Current antimicrobial therapy options for CDI are very limited.19
Clinical response to metronidazole is inferior at the end of therapy
compared with vancomycin in patients with severe CDI.20,21
Isolates showing reduced susceptibility to metronidazole have
been reported,16 and whilst no link between clinical outcome
and the MIC of metronidazole has been established, elevated
MICs in conjunction with low intraluminal antibiotic concentra-
tions following oral administration may affect efficacy. Both
vancomycin and metronidazole are associated with high rates
of recurrent disease with 20%–30% of subjects experiencing a
recurrent infection following the primary episode; recurrence
rates may be .65% following a third episode of CDI.22
Recurrent CDI remains frustratingly difficult to treat, with a dele-
terious impact on patient welfare and healthcare system
resources. The recently approved fidaxomicin has been shown in
Phase 3 clinical studies to be non-inferior in clinical response to
vancomycin at the end of treatment and to be superior in sus-
tained clinical response to 25 days post end of therapy with
an overall reduction in rates of recurrence compared with vanco-
mycin. However, recurrence rates were comparable for vanco-
mycin and fidaxomicin for subjects infected with C. difficile BI
(ribotype 027) strains.23,24 New agents, particularly those
that reduce rates of recurrent disease, are required to effectively
manage CDI.
The studies described here show that SMT19969 resulted
in potent inhibition of a range of C. difficile clinical isolates,
consistent with previously reported in vitro activity against
C. difficile.14,15 Compared with vancomycin and metronidazole,
SMT19969 was considerably more potent; MIC90 values were
typically 16-fold lower, with consistent activity against a range
of clinically relevant ribotypes. Fidaxomicin showed increased
potency compared with SMT19969 with MIC90 values one dilu-
tion and MIC50 values two dilutions lower than those recorded
for SMT19969.
In addition to potent growth inhibition, SMT19969was bacteri-
cidal against three C. difficile clinical isolates representing ribo-
types 027, 012 and 078. Against C. difficile BI1, SMT19969
resulted in a .3 log10 reduction in viable counts following 24 h
of exposure, with viable counts typically reduced to below the
LOD of the assay; fidaxomicin showed reduced killing at 24 h
with typical log10 reductions in cfu/mL of 1.5–2.0 (although at
20×MIC viable counts were reduced by 3.3 log10 cfu/mL).
Slightly reduced killing by SMT19969 of strain 5325 was observed
at concentrations ≤5×MIC. Against C. difficile 630 and 5325,
fidaxomicin was bactericidal at all concentrations above the MIC
and, consistent with previous reports, killing by fidaxomicin was
time dependent.25
Killing by vancomycinwas largely independent of drug concen-
tration, and in accordance with previous results,26 vancomycin
was bacteriostatic. In addition, vancomycin was shown to be
associated with a minimal PAE (typically 0–2 h), as reported pre-
viously.18,26 SMT19969, at concentrations ≥5×MIC, was asso-
ciated with a pronounced PAE with no growth recovery observed
following a 1 h exposure to 20×MIC. Although higher concentra-
tions of SMT19969 were required to effect a prolonged PAE, mean
faecal concentrations of 1363 mg/g (SD+446), more than three
orders of magnitude higher than the MIC90 of SMT19969 for
C. difficile, were observed in Phase 1 healthy volunteers receiving
200 mg twice daily for 10 days.27 As previously reported, fidaxo-
micin showed a very prolonged PAE, typically 8–20 h, at all
concentrations.18
The data reported here show that SMT19969 has potent and
consistent activity against the examined C. difficile strains. In add-
ition, SMT19969 was bactericidal against all strains tested, and
was associated with a pronounced PAE at higher concentrations,
as would be expected in the gastrointestinal tract of CDI subjects.
In conjunction with its narrow spectrum of activity,14,15 these
data support continued investigation of SMT19969 as a potential
therapy for CDI.
Table 4. PAE for SMT19969, vancomycin and fidaxomicin against
C. difficile BI1, 630 and 5325
Strain Agent
PAE (h)
1×MIC 2×MIC 5×MIC 10×MIC 20×MIC
BI1 SMT19969 0 0 2 8–20 .20
vancomycin 0 0 0 0 0
fidaxomicin 0 8–20 8–20 8–20 NE
5325 SMT19969 0 0 0 4 NE
vancomycin 0 2 2 0 0
fidaxomicin 8–20 8–20 8–20 8–20 .20
630 SMT19969 0 2 2 4 .20
vancomycin 0 0 0 0 2
fidaxomicin 8–20 8–20 8–20 .20 .20
NE, not established due to inconsistent growth recovery (see the text).
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